查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
心房颤动手术市场-增长、趋势、COVID-19 影响和预测 (2023-2028)
市场调查报告书
商品编码
1189880

心房颤动手术市场-增长、趋势、COVID-19 影响和预测 (2023-2028)

Atrial Fibrillation Surgery Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 115 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在预测期内（2022-2027 年），房颤手术市场预计将以 12.2% 左右的复合年增长率增长。

在COVID-19中，心血管疾病患者处于高危状态，最有可能出现心肌炎、节律紊乱等多器官功能衰竭。 来自中国武汉的数据显示，心律失常和急性心肌损伤是 COVID-19 确诊阳性病例中最常见的心臟并发症。 此外，在 2020 年 2 月发表在美国医学会杂誌 (JAMA) 上的病例报告中，休克 (8.7%)、急性呼吸窘迫综合征 (19.6%)、心律失常 (16.7%) 和急性心肌损伤 (17.2%)已经确认。 与在 ICU 外接受治疗的患者相比，在 ICU 接受治疗的患者也更容易出现其中一种并发症。

此外，由于 COVID-19 不断演变的公共卫生危机，远程监控使临床医生能够在需要时与医疗保健专业人员和患者保持关係。 医疗保健提供者可以在患者在家时远程访问患者的健康信息，从而减少去医院就诊的需要并将暴露于 COVID-19 的风险降至最低。 需要开发新技术和数字平台来支持远程医疗，还需要进一步研究远程医疗、持续数据收集、先进车辆能力和远程患者监控的作用，以指导最佳实践。是的，并可能推动增长研究目标市场。

房颤市场受到全球肥胖和心脏病患病率上升的推动。 此外，心脏病是全世界死亡的主要原因之一，生活方式的改变正在迅速增加患有心脏病的人数。

此外，新产品不断推向市场，进一步推动了市场增长。 例如，2022 年 4 月，AtriCure, Inc. 在美国推出了 EnCompass Clamp，这是 Isolator Synergy Ablation System 的一部分。 EnCompass 钳具有 FDA 510(k) 心臟手术期间心臟组织消融许可，旨在使同步手术消融更有效。

此外，突显心房颤动市场进步的不断增加的研发程序也将提振市场。 例如，2022 年 1 月，Peerbridge Health 与 Northwell Health 合作推出了新的 AFib 卓越中心，这是一项旨在优化心房颤动 (AFib) 患者护理的多学科工作。 在 Peerbridge 的支持下，Northwell 的 AFib 卓越中心将开展一项试点计划，重点关注未确诊阻塞性睡眠呼吸暂停 (OSA) 的 AFib 患者。 该试点项目将帮助心脏病学和睡眠医学医师更好地了解这两种疾病之间的重要联繫，以及如何最好地同时快速有效地治疗心房颤动和 OSA。旨在 因此，房颤药物的进步有望推动市场。

因此，由于上述因素，市场有望在预测期内增长。 然而，与这些设备相关的高治疗成本和监管问题预计会阻碍市场增长。

主要市场趋势

门诊手术中心部分预计在预测期内有良好的增长

由于强大的医疗保健基础设施、熟练劳动力的可用性和负担能力，预计门诊手术中心部分将实现良好增长。 此外，预计该市场将受到患有动脉硬化和心力衰竭等生活方式相关疾病的患者数量增加以及老年人口增加的推动。 然而，与传统手术相比，微创手术的优势最终将导致细分市场的增长。 手术疼痛、受伤、住院时间更短、准确性更高和恢復时间更快等优势正在促使患者选择微创手术，这有望推动市场增长。

多种服务的增加以及门诊手术中心的进步将进一步推动市场增长。 例如，2021 年 1 月，HST Pathways 推出了“HST One”，这是门诊手术中心 (ASC) 的首要会员计划。 该会员计划将允许最终用户选择捆绑的流行产品作为其会员资格的一部分，并可以根据需要灵活地添加服务。 以这种方式在门诊手术中心提供定制服务有望吸引更多患者并显着扩大市场。

另外，随着肥胖的增加，患心房颤动的人数也在增加。 因此，肥胖的增加被认为有助于市场增长。

此外，在 2022 年 4 月发表的论文“传统非卧床和独立门诊设置中心房颤动的导管消融后当天出院”中，接受导管消融治疗 AF 的患者的围手术期管理已被证明类似于接受门诊手术的患者。 因此，门诊手术中心在促进房颤手术方面的进步将促进该领域的增长。

因此，由于上述因素，预计研究部门将对市场增长做出重大贡献。

北美将是预测期内的主要增长部分

预计北美地区将主导房颤市场。 这主要是由于患者数量的增加和该地区大公司的存在。 北美地区的美国预计将主导市场增长。 根据CDC（美国疾病控制与预防中心）提供的统计数据，2021年9月，预计2030年美国将有1210万人患房颤，未来有望增长。

由于主要参与者在该国的存在，技术进步和优惠保险政策的可用性促进了美国研究市场的增长。 例如，2020 年 7 月，波士顿科学公司推出了 WATCHMAN FLX 左，用于降低需要口服抗凝治疗替代治疗的非瓣膜性心房颤动 (NVAF) 患者的中风风险。获得美国食品和药物管理局批准用于心耳闭合 (LAAC) 装置。

同样在 2022 年 2 月，美敦力公司获得了美国食品和药物管理局批准的 Freezor 和 Freezor Xtra 心臟冷冻消融聚焦导管，用于治疗增加的小儿房室折返性心动过速 (AVNRT) 我得到

此外，证明现有产品功效的研发在该地区很活跃，从而促进了这些产品的采用并推动了市场发展。 例如，2022年4月，CathVision宣布在佛蒙特大学医学中心完成CathVision ECGenius系统临床评估试验的患者入组。 ECGenius 代表了 ECG 信号采集、解释和治疗支持质量的重大进步，有助于正确诊断和设计复杂心律失常（包括心房颤动 (AF)）的消融策略。

因此，由于上述因素，所研究的市场预计在研究期间会在同一地区增长。

竞争格局

这个市场分散且竞争激烈。 房颤市场由专注于开发新产品发布和见证新进入者市场渗透的本地和全球参与者组成。 技术进步和对改善医疗保健系统的关注可能会影响更多公司进入市场，从而进一步推动未来的市场增长。 市场上的主要参与者是波士顿科学公司、美敦力公司、Biotronik、AtriCure Inc.、Cardiofocus Inc.等。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动力
    • 肥胖和日益加重的心脏病负担
    • 提高公众意识的计划数量增加
  • 市场製约因素
    • 手术费用高
    • 与设备相关的监管问题
  • 五力分析分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：单位：百万美元）

  • 按产品分类
    • 导管消融
    • 外科消融
  • 最终用户
    • 医院
    • 门诊手术中心
    • 其他最终用户
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东和非洲
      • 海湾合作委员会国家
      • 南非
      • 其他中东和非洲地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章竞争格局

  • 公司简介
    • Boston Scientific Corporation
    • Medtronic PLC
    • Biotronik SE & Co. KG
    • AtriCure Inc.
    • Cardiofocus Inc.
    • Abbott Laboratories
    • Johnson & Johnson
    • MicroPort Scientific Corporation
    • Koninklijke Philips NV
    • Siemens AG
    • Osypka AG
    • Kardium Inc.

第7章 市场机会今后动向

简介目录
Product Code: 67135

The Atrial Fibrillation Surgery Market is expected to register a CAGR of nearly 12.2% during the forecast period (2022-2027).

COVID-19 patients with cardiovascular disorders are at high risk and are most vulnerable to multiple organ failures, including myocarditis and rhythm disturbance. The data from Wuhan, China, has indicated that arrhythmia and acute cardiac injury were amongst the most prevalent heart complications in confirmed-positive cases of COVID-19. Furthermore, the February 2020 case report in the Journal of the American Medical Association (JAMA) identified common complications, such as shock (8.7%), acute respiratory distress syndrome (19.6%), arrhythmia (16.7%), and acute cardiac injury (17.2%) among hospitalized patients. Moreover, patients who received care in the ICU were more likely to have one of these complications than non-ICU patients.

Moreover, owing to the evolving public health crisis of COVID-19, remote monitoring allows clinicians to maintain necessary patient rapport with their healthcare provider when required. Healthcare providers can access information remotely about a patient's health while the patient is at home, which will reduce the need for hospital visits and minimize the risk of exposure to COVID-19. New technologies and digital platforms to aid in remote care should be developed, and further research on the role of telehealth, continuous data collecting, advanced automotive features, and remote patient monitoring is needed to guide best practices, which may fuel the growth of the studied market.

The atrial fibrillation market is driven by the rising prevalence of obesity and heart diseases across the globe. Additionally, heart diseases are one of the major causes of mortality across the globe, and due to the changing lifestyle, the number of people suffering from heart diseases is growing rapidly.

Additionally, the launch of new products in the market will further boost the market growth. For instance, in April 2022, AtriCure, Inc. launched the EnCompass Clamp, a part of the Isolator Synergy Ablation System in United States. The EnCompass Clamp received FDA 510(k) clearance for ablation of cardiac tissue during cardiac surgery and is designed to make concomitant surgical ablations more efficient.

Furthermore, the rising research and development procedures highlighting the advancements in the Atrial fibrillation market will also boost the market. For instance, in January 2022, Peerbridge Health collaborated with Northwell Health on their newly launched AFib Center of Excellence, a multi-disciplinary effort that optimizes treatment for patients with atrial fibrillation (AFib). With Peerbridge's support, Northwell's AFib Center of Excellence will conduct a pilot program focusing on AFib patients with undiagnosed obstructive sleep apnea (OSA). The pilot aims to help cardiology and sleep physicians better understand the critical link between the two conditions and how best to quickly and effectively treat AFib and OSA concurrently. Thus, advancements in atrial fibrillation therapeutics are expected to drive the market.

Hence, owing to the aforementioned factors, the market studied is expected to grow in the forecast period. However, the high cost of procedures and regulatory issues associated with these devices is expected to hinder the market growth.

Key Market Trends

The Ambulatory Surgical Center Segment is Expected to Witness Good Growth over the Forecast Period

The ambulatory surgical center segment is expected to witness good growth due to enhanced healthcare infrastructure, availability of skilled labor, and affordability. The rising patient pool and growing geriatric population suffering from lifestyle diseases, such as atherosclerosis and heart failure, are expected to propel the market. However, compared to conventional surgeries, the benefits of minimally invasive surgeries will ultimately lead to segment growth. Benefits, such as reduced surgical pain, injury, hospital stay, higher accuracy, and speedy recovery time, are encouraging patients to opt for minimally invasive surgeries, which is expected to boost the market growth.

The addition of multiple services in advancing ambulatory surgical centers will further drive the market growth. For instance, in January 2021, HST Pathways launched a premier membership program for ambulatory surgery centers (ASCs), "HST One." This membership program will enable its end-user to select bundled popular products as part of their membership, with the flexibility to add additional services as needed. Such initiation of delivering customized services at ambulatory surgical centers will attract a greater number of patients and will lead to significant growth of the market.

In addition, owing to the increasing burden of obesity, there is an increase in the number of people suffering from atrial fibrillation. Hence, it is believed that an increased prevalence of obesity is contributing to the growth of the market.

Furthermore, the article "Same-Day Discharge After Catheter Ablation of Atrial Fibrillation in Traditional Nonambulatory and Freestanding Ambulatory Settings" published in April 2022, the periprocedural management of patients who receive catheter ablation for AF is similar to those undergoing ambulatory surgery. Thus, such advancements in ambulatory surgical centers for the smooth transition of atrial fibrillation surgeries will drive the segment growth.

Thus, due to the above-mentioned factors, the studied segment is expected to contribute significantly to market growth.

North America is the Major Growing Segment Over the Forecast Period

The North American region is expected to dominate the atrial fibrillation market. This is majorly attributed to the rising patient pool in the region and the presence of key players. United States within the North American region is expected to dominate the market growth. As per the statistics provided by the CDC (Centre for Disease Control and Prevention), in September 2021, it is estimated that 12.1 million people in United States will have atrial fibrillation in 2030, and with the rising geriatric population, it is expected that the demand for the studied market will grow in the future.

With the presence of key players in the country, technological advancements and the availability of favorable insurance policies are augmenting the growth of the market studied in United States. For instance, in July 2020, Boston Scientific Corporation received United States Food and Drug Administration approval for the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device, which is indicated to reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) who requires alternative to oral anticoagulation therapy.

Additionally, in February 2022, Medtronic plc received United States Food and Drug Administration approval for Freezor and Freezor Xtra Cardiac Cryoablation Focal Catheters to treat the growing prevalence of pediatric Atrioventricular Nodal Reentrant Tachycardia (AVNRT).

Furthermore, growing research and development for proving the efficacies of existing products in the region will increase their adoption, thereby driving the market. For instance, in April 2022, CathVision reported the completion of patient enrollment in the CathVision ECGenius System clinical evaluation study at the University of Vermont Medical Center. ECGenius represents an important evolution in the quality of ECG signal acquisition, interpretation, and therapy support which help in correctly diagnosing and devising ablation strategies for complex arrhythmias, including atrial fibrillation (AF).

Thus, due to the above-mentioned factors, the studied market is expected to grow in the region during the study period.

Competitive Landscape

The studied market is fragmented and moderately competitive. The market for atrial fibrillation consists of local as well as global companies, which are focusing on the development of new product launches and also witnessing the penetration of new entrants in the market. Technological advancements and the focus on improving the healthcare system are expected to influence more companies to enter the market, further driving market growth in the future. Major key players in the market include Boston Scientific Corporation, Medtronic Plc, Biotronik, AtriCure Inc., and Cardiofocus Inc., among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Burden of Obesity and Heart Diseases
    • 4.2.2 Rising Number of Programs to Enhance Public Awareness
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Procedure
    • 4.3.2 Regulatory Issues Associated with the Devices
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - in USD Million)

  • 5.1 By Product
    • 5.1.1 Catheter Ablation
    • 5.1.2 Surgical Ablation
  • 5.2 By End User
    • 5.2.1 Hospitals
    • 5.2.2 Ambulatory Surgical Centers
    • 5.2.3 Other End Users
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Boston Scientific Corporation
    • 6.1.2 Medtronic PLC
    • 6.1.3 Biotronik SE & Co. KG
    • 6.1.4 AtriCure Inc.
    • 6.1.5 Cardiofocus Inc.
    • 6.1.6 Abbott Laboratories
    • 6.1.7 Johnson & Johnson
    • 6.1.8 MicroPort Scientific Corporation
    • 6.1.9 Koninklijke Philips NV
    • 6.1.10 Siemens AG
    • 6.1.11 Osypka AG
    • 6.1.12 Kardium Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS